Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by aldo451on Aug 19, 2020 11:38am
273 Views
Post# 31428558

The big boys are not bailing...

The big boys are not bailing...as some of the bashers on this board would have you believe.

FAQ section of Liminal's website:

What is the purpose of the F-1 recently filed with the SEC and posted on Edgar and SEDAR?

The registration statement on Form F-1 filed on August 13th (the “Resale F-1”) is not an offering of common shares by Liminal BioSciences Inc. (the “Company”).

The Resale F-1 registers the common shares previously issued in April 2019 to our majority shareholders Structured Alpha LP (“SALP”) and to funds managed by Consonance Capital Management (“Consonance”) to allow for the resale of such shares by SALP and Consonance on the Nasdaq stock exchange now that our shares are listed on the Nasdaq Stock Exchange.

The filing of the Resale F-1 allows the Company to meet its contractual obligations with respect to Consonance and replaces the prospectus supplement filed by the Company in both Canada and the United States to the Company’s previous registration statement and shelf prospectus filed on November 15, 2019 that has since expired.

Copies of the Resale F-1 can be found on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

<< Previous
Bullboard Posts
Next >>